Overall, while PD-L1 remains the key clinical biomarker, research from 2018 to 2025 has broadened our understanding that HNSCC response to immunotherapy depends on a complex interplay of viral status, mutational landscape, and the tumor immune contexture [60,61,62,63,64]. The gene discussed is CD274; the disease is neoplasm.